Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.57 |
| ▸ | CCR1 | P32246 | 1/20 | 0.54 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.49 |
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28496074 | 0.98 | CYSLTR1 (0.56) | CYSLTR1CCR1CYSLTR2CYP1A2GPBAR1 | |
| Hydrochloric Acid SCHEMBL3129974 | 0.98 | CYSLTR1 (0.56) | CYSLTR1CCR1CYSLTR2CYP1A2GPBAR1 | |
| Bicarbonate SCHEMBL28680175 | 0.92 | CYP1A2 (0.56) | CYSLTR1CCR1CYSLTR2CYP1A2GPBAR1 | |
| Sulfuric Acid SCHEMBL3119154 | 0.90 | CYSLTR1 (0.50) | CYSLTR1CCR1CYSLTR2CYP1A2GPBAR1 | |
| SCHEMBL6145547 | 0.84 | AR (0.56) | CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL296473 | 0.83 | PDE10A (0.50) | CYSLTR1CYSLTR2CYP1A2GPBAR1PDE10A | |
| SCHEMBL30879956 | 0.81 | CYSLTR1 (0.57) | CYSLTR1CYSLTR2CYP1A2PDE10ANCF1 | |
| SCHEMBL2913941 | 0.81 | PDE10A (0.61) | CYSLTR1CYSLTR2CYP1A2PDE10ANCF1 | |
| SCHEMBL3267444 | 0.81 | CYSLTR1 (0.57) | CYSLTR1CYSLTR2CYP1A2PDE10ANCF1 | |
| SCHEMBL898777 | 0.79 | PDE10A (0.47) | CYSLTR1CYSLTR2CYP1A2GPBAR1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 782 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114213307-A | Preparation method of N-alkyl substituted pyrrolidone compound | 河南农业大学 | 2022-03-22 | — | — | CN | claimed |
| CN-110963991-A | PI3K inhibitor and preparation method and application thereof | 嘉兴学院 | 2020-04-07 | — | — | CN | claimed |
| WO-2010000686-A2 | COMPOSITION FOR TOPICAL USE | VISENTINI FEDERICO (BR) | 2010-01-07 | — | — | WO | claimed |
| CN-101528718-A | Modulators of glucocorticoid receptor and/or AP-1 and/or NF- κ B activity and uses thereof | BRISTOL MYERS SQUIBB CO (US) | 2009-09-09 | — | — | CN | claimed |
| CN-100502847-C | Compositions containing substituted quinolines and substituted diphenyl sulfones and its pharmaceutical use | BAYER COLLEGE OF MEDICINE (US) | 2009-06-24 | — | — | CN | claimed |
| EP-2049507-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AND/OR AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | Brystol-Myers Squibb Company (US) | 2009-04-22 | — | — | EP | claimed |
| US-20090075995-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-19 | — | — | US | claimed |
| EP-1594485-A4 | COMPOSITIONS CONTAINING SUBSTITUTED QUINOLINES AND SUBSTITUTED DIPHENYL SULFONES AND METHODS OF USE | BAYLOR COLLEGE MEDICINE (US) | 2009-01-14 | — | — | EP | claimed |
| WO-2008021926-A2 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AND/OR AP-1, AND/OR NF-KB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | claimed |
| CN-1819822-A | Compositions containing substituted quinolines and substituted diphenyl sulfones and methods of use | BAYER COLLEGE OF MEDICINE (US) | 2006-08-16 | — | — | CN | claimed |
| WO-1997007145-A1 | THERMOSETTING ANTI-REFLECTIVE COATINGS AND METHOD FOR MAKING SAME | FLAIM TONY D (US) | 1997-02-27 | — | — | WO | claimed |
| EP-0610943-A1 | Pyridinium derivatives useful as PAF antagonists | J. URIACH & CIA. S.A. (ES) | 1994-08-17 | — | — | EP | claimed |
| US-5324747-A | Treatment of inflammatory diseases | HOFFMANN-LA ROCHE INC. (US) | 1994-06-28 | — | — | US | claimed |
| EP-0579066-A2 | N-substituted anilines | F. HOFFMANN-LA ROCHE AG (CH) | 1994-01-19 | — | — | EP | claimed |
| US-5166161-A | Antiallergens or antiinflammatory agents | PFIZER INC. (US) | 1992-11-24 | — | — | US | claimed |
| EP-0414076-A1 | Cyclic substituted (quinoline-2-yl-methoxy)phenylacetic acid derivatives | BAYER AG (DE) | 1991-02-27 | — | — | EP | claimed |
| CN-1045778-A | (quinolin-2-ylmethoxy) phenyl-N that replaces, N '-sulfonylurea, its preparation method and the application in medicine thereof | BAYER AG (DE) | 1990-10-03 | — | — | CN | claimed |
| EP-0181568-A2 | Anti-inflammatory/anti-allergic compounds | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1986-05-21 | — | — | EP | claimed |
| EP-0021337-B1 | PREPARATIONS FOR PARENTERAL ADMINISTRATION OF FAT-SOLUBLE DRUGS | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1983-12-07 | — | — | EP | claimed |
| US-4411894-A | Pharmaceutical preparations | HOFFMANN-LA ROCHE INC. (US) | 1983-10-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075995-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NFKB2, NFRKB, NFKB1 | CYSLTR1 385/4885CCR1 197/4885CYSLTR2 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.